Drugmaker Dr. Reddy’s Laboratories has launched Gilead Sciences Remdesivir, an investigational drug used in the treatment of COVID-19, under the brand name Redyx in India.
Drugs Controller General of India (DCGI) has approved Remdesivir for restricted emergency use in the treatment of COVID-19 patients hospitalised with severe symptoms.
Dr.Reddy's said the launch is part of the licensing agreement with Gilead Sciences Inc. that grants it the right to register, manufacture and sell Remdesivir in 127 countries, including India.
Redyx is available in strength of 100 mg vial, the company said.
CEO, Branded Markets (India and Emerging Markets) at Dr. Reddy’s M.V.Ramana said, "We will continue our efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
